<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00386321</url>
  </required_header>
  <id_info>
    <org_study_id>TH011103</org_study_id>
    <nct_id>NCT00386321</nct_id>
  </id_info>
  <brief_title>Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Yt90Zevalin Plus CHOP, Z-CHOP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the treatment of Yt90 Zevalin in&#xD;
      combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)are&#xD;
      effective as first line treatment in patients with bulky stage II or stage III or IV diffuse&#xD;
      large B-cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radioimmunotherapy represents a significant advance over unlabeled immunotherapy for the&#xD;
      treatment of patients with B-cell non-Hodgkin's lymphoma. The radiobiological effects&#xD;
      associated with Yt90-labelled ibritumomab tiuxetan (Zevalin) include the induction of&#xD;
      apoptosis and cell-cycle redistribution.&#xD;
&#xD;
      The response rate tend to be higher in patients who have been treated with fewer prior&#xD;
      therapies and Yt90-labelled ibritumomab tiuxetan may be suitable for use early in the course&#xD;
      of therapy.&#xD;
&#xD;
      Yt90-labelled ibritumomab tiuxetan has less non hematologic toxicity than chemotherapy, with&#xD;
      only minimal alopecia, mucositis, nausea, or vomiting, and a lower incidence of infections.&#xD;
&#xD;
      Yt90-labelled ibritumomab tiuxetan regimen is routinely and safely given in an outpatient&#xD;
      setting and is completed in 7-9 days and is thus more convenient to be used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Participants are no longer being examined or treated.&#xD;
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year progression-free survival and overall survival of patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (partial response, complete unconfirmed response, and complete response)in patients</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year progression-free survival, overall survival and response rate in BCL-2 positive patients</measure>
  </secondary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed CD20 positive diffuse large B-cell lymphoma with bulky stage&#xD;
             II or stage III or stage IV&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  Performance status Zubrod 0-2&#xD;
&#xD;
          -  Less than 20,000/mcL circulating lymphoid cells on WBC differential count&#xD;
&#xD;
          -  No clinical evidence of CNS involvement, no prior diagnosis of indolent lymphoma, no&#xD;
             histologic transformation&#xD;
&#xD;
          -  Ejection fraction more than or equal to 45% by MUGA or no significant abnormality by&#xD;
             echocardiogram&#xD;
&#xD;
          -  Fertile patients with effective contraception method&#xD;
&#xD;
          -  No other malignancy within past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer, stage I or II cancer in complete remission, or carcinoma in&#xD;
             situ of cervix&#xD;
&#xD;
          -  No HIV positive, no prior solid organ transplantation&#xD;
&#xD;
          -  No prior antibody therapy, chemotherapy, radiotherapy for lymphoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum creatinine ot bilirubin more than 2.5 X ULN unless due to lymphoma&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Concurrent severe and/or uncontrolled medical disease which could compromise&#xD;
             participation in the study&#xD;
&#xD;
          -  Patients with more than 25% infiltrated bone marrow&#xD;
&#xD;
          -  Patients with platelet counts less than 100,000/mcL or neutrophil counts less than&#xD;
             1,500/mcL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Udomsak Bunworasate, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hematology and Stem Cell Transplant, Department of Medicine, Faculty of Medicine, Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>October 10, 2006</study_first_submitted>
  <study_first_submitted_qc>October 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>November 17, 2010</last_update_submitted>
  <last_update_submitted_qc>November 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2010</last_update_posted>
  <keyword>Zevalin</keyword>
  <keyword>Zevalin plus CHOP</keyword>
  <keyword>Diffuse large B-cell lymphoma</keyword>
  <keyword>First line Diffuse large B-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

